Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.71 EUR | +0.57% | -2.47% | +65.12% |
04-08 | Sensorion: completion of a private placement | CF |
04-05 | Sensorion SA announced that it expects to receive ?15 million in funding | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+65.12% | 208M | - | ||
+2.17% | 42.75B | B | ||
+47.81% | 41.61B | A | ||
+12.30% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.53% | 25.49B | B- | ||
-23.57% | 18.12B | B | ||
+30.80% | 12.24B | C+ | ||
-1.85% | 11.76B | C+ | ||
+8.54% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALSEN Stock
- Ratings Sensorion